Evidence map›Paper›PMID 24238714›Full record

Trial reportJournal of substance abuse treatment2014

Leaving buprenorphine treatment: patients' reasons for cessation of care.

Jan Gryczynski, Shannon Gwin Mitchell, Jerome H Jaffe, Kevin E O'Grady, Yngvild K Olsen, Robert P Schwartz

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of substance abuse treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jan GryczynskiFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA. Electronic address: jgryczynski@friendsresearch.org.
Shannon Gwin MitchellFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Jerome H JaffeFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD 21201, USA.
Kevin E O'GradyUniversity of Maryland, College Park, Department of Psychology, College Park, MD 20742, USA.
Yngvild K OlsenInstitutes for Behavior Resources, Inc., REACH Health Services, Baltimore, MD 21218, USA.
Robert P SchwartzFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Friends Research Institute · USInstitutes for Behavior Resources · USUniversity of Maryland, College Park · US

Funding

Intensive Outpatient v. Outpatient Treatment with Buprenorphine among African AmeRC1DA028407 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI MITCHELL, SHANNON GWIN · 2009 to 2010
$990k
NIDA NIH HHS 1RC1DA028407NIDA NIH HHS RC1 DA028407
6 · The paper itself

Abstract

Many opioid-dependent patients leave treatment prematurely. This study is a planned secondary analysis from a randomized trial of counseling for African Americans (N=297) entering buprenorphine treatment at one of two outpatient programs. This study examines: (1) whether patients' initial treatment duration intentions prospectively predict retention; and (2) patients' reasons for leaving treatment. Participants were queried about their treatment duration intentions at treatment entry, and their reasons for leaving treatment at 6-month follow-up. At baseline, 28.0% reported wanting to stay in buprenorphine treatment less than 6 months, while 42.1% actually left buprenorphine treatment within 6 months. However, participants intending short-term buprenorphine at the outset were not at elevated risk of early treatment discontinuation (OR=1.15; p=.65). Participants attributed treatment cessation predominantly to conflicts with staff, involuntary discharge, and perceived inflexibility of the program. Future research should examine patient-centered models of buprenorphine treatment that could improve retention.

Indexed as

Patient DropoutsAdultAnalgesics, OpioidBlack or African AmericanBuprenorphineCounselingFemaleHumansMaleMiddle AgedOpioid-Related DisordersAnalgesics, OpioidBuprenorphineBuprenorphineDropoutOpioid dependencePatient intentionsRetention

Identifiers

PMID24238714
PMCPMC3947058
OpenAlexW1970939183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.